Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1975 1
1976 2
1984 1
1985 1
1986 1
1987 1
1988 1
1990 1
1991 3
1992 2
1993 1
1994 2
1995 3
1996 1
2000 2
2002 2
2003 1
2005 1
2008 1
2009 1
2013 1
2015 1
2016 2
2017 5
2018 9
2019 5
2020 2
2021 4
2022 4
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Dominant negative effectors of heparin affin regulatory peptide (HARP) angiogenic and transforming activities.
Bernard-Pierrot I, Delbé J, Rouet V, Vigny M, Kerros ME, Caruelle D, Raulais D, Barritault D, Courty J, Milhiet PE. Bernard-Pierrot I, et al. Among authors: barritault d. J Biol Chem. 2002 Aug 30;277(35):32071-7. doi: 10.1074/jbc.M202747200. Epub 2002 Jun 17. J Biol Chem. 2002. PMID: 12070152 Free article.
Recently, we have demonstrated that the C-terminal residues 111-136 of HARP are required for its mitogenic and transforming activities (Bernard-Pierrot, I., Delbe, J., Caruelle, D., Barritault, D., Courty, J., and Milhiet, P. E. (2001) J. Biol. Chem. 276, 12228-1223 …
Recently, we have demonstrated that the C-terminal residues 111-136 of HARP are required for its mitogenic and transforming activities (Bern …
Characteristics of H3K27M-mutant diffuse gliomas with a non-midline location.
Guidara S, Seyve A, Poncet D, Leonce C, Bringuier PP, McLeer A, Sturm D, Cartalat S, Picart T, Ferrari A, Hench J, Frank S, Meyronet D, Ducray F, Barritault M. Guidara S, et al. Among authors: barritault m. J Neurooncol. 2024 Sep;169(2):391-398. doi: 10.1007/s11060-024-04733-z. Epub 2024 Jun 27. J Neurooncol. 2024. PMID: 38937309
Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC.
Hofman V, Heeke S, Bontoux C, Chalabreysse L, Barritault M, Bringuier PP, Fenouil T, Benzerdjeb N, Begueret H, Merlio JP, Caumont C, Piton N, Sabourin JC, Evrard S, Syrykh C, Vigier A, Brousset P, Mazieres J, Long-Mira E, Benzaquen J, Boutros J, Allegra M, Tanga V, Lespinet-Fabre V, Salah M, Bonnetaud C, Bordone O, Lassalle S, Marquette CH, Ilié M, Hofman P. Hofman V, et al. Among authors: barritault m. JTO Clin Res Rep. 2022 Dec 29;4(2):100457. doi: 10.1016/j.jtocrr.2022.100457. eCollection 2023 Feb. JTO Clin Res Rep. 2022. PMID: 36718140 Free PMC article.
Characteristics of cerebellar glioblastomas in adults.
Picart T, Barritault M, Berthillier J, Meyronet D, Vasiljevic A, Frappaz D, Honnorat J, Jouanneau E, Poncet D, Ducray F, Guyotat J. Picart T, et al. Among authors: barritault m. J Neurooncol. 2018 Feb;136(3):555-563. doi: 10.1007/s11060-017-2682-7. Epub 2017 Dec 1. J Neurooncol. 2018. PMID: 29196927
Gyriform infiltration as imaging biomarker for molecular glioblastomas.
Mesny E, Barritault M, Izquierdo C, Poncet D, d'Hombres A, Guyotat J, Jouanneau E, Ameli R, Honnorat J, Meyronet D, Ducray F. Mesny E, et al. Among authors: barritault m. J Neurooncol. 2022 May;157(3):511-521. doi: 10.1007/s11060-022-03995-9. Epub 2022 Apr 1. J Neurooncol. 2022. PMID: 35364762
Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA Network.
Esparragosa Vazquez I, Sanson M, Chinot OL, Fontanilles M, Rivoirard R, Thomas-Maisonneuve L, Cartalat S, Tabouret E, Appay R, Bonneville-Levard A, Darlix A, Meyronet D, Barritault M, Gueyffier F, Remontet L, Maucort-Boulch D, Honnorat J, Dehais C, Ducray F; POLA Network. Esparragosa Vazquez I, et al. Among authors: barritault m. Neurooncol Adv. 2024 May 27;6(1):vdae078. doi: 10.1093/noajnl/vdae078. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38855053 Free PMC article.
A synthetic glycosaminoglycan mimetic binds vascular endothelial growth factor and modulates angiogenesis.
Rouet V, Hamma-Kourbali Y, Petit E, Panagopoulou P, Katsoris P, Barritault D, Caruelle JP, Courty J. Rouet V, et al. Among authors: barritault d. J Biol Chem. 2005 Sep 23;280(38):32792-800. doi: 10.1074/jbc.M504492200. Epub 2005 Jul 13. J Biol Chem. 2005. PMID: 16014624 Free article.
In a previous study, we showed that in situ injection of glycosaminoglycan mimetics called RGTAs (ReGeneraTing Agents) enhanced neovascularization after skeletal muscular ischemia (Desgranges, P., Barbaud, C., Caruelle, J. P., Barritault, D., and Gautron, J. (1999) FASEB J …
In a previous study, we showed that in situ injection of glycosaminoglycan mimetics called RGTAs (ReGeneraTing Agents) enhanced neovasculari …
[Multiple lung carcinoma: Primary or intrapulmonary metastasis?].
Ravella L, Barritault M, Bringuier PP, Chalabreysse L, Thivolet-Bejui F, Maury JM, Duruisseaux M, Brevet M. Ravella L, et al. Among authors: barritault m. Ann Pathol. 2018 Jun;38(3):202-205. doi: 10.1016/j.annpat.2018.02.001. Epub 2018 Mar 17. Ann Pathol. 2018. PMID: 29555057 French.
60 results